Effects of suramin on complement, blood clotting, fibrinolysis and kinin formation
Explore this paper's citation graph
Summary
The inhibition by suramin of complement components, and of blood clotting, fibrinolytic, and plasma kinin forming factors depended on the conditions of the assay and on the substrates used.
- Type
- article
- Published
- 1973-12-01
- Cited by
- 42
- References
- 18
- Access
- Open access
- OpenAlex
- https://openalex.org/W1998217883
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:23449925
Keywords
Suramin, Fibrinolysis, Kinin, Medicine, Complement (music)
References
- Suramin--a potent reversible and competitive inhibitor of complement systems.
- Studies on suramin; the action of the drug on some enzymes.
- An analogue of guinea pig C8: in vitro generation and inhibitory activity.
- C′l activation in hereditary angioneurotic edema plasma: role of urokinase and inhibitors
- ANTIGEN-ANTIBODY CROSSED ELECTROPHORESIS.
- REACTIVE LYSIS: THE COMPLEMENT-MEDIATED LYSIS OF UNSENSITIZED CELLS
- Observations on intrinsic kinin‐forming factors in human plasma: the effect of acid, acetone, chloroform, heat and euglobulin separation on kinin formation
- Intrinsic activation of plasma kinin formation and complement.
- Activation of arginine and tyrosine esterase in serum from patients with hereditary angio‐oedema
- Reaction mechanism of the alternative pathway of complement fixation.
- THE KAOLIN CLOTTING TIME
- REACTIVE LYSIS: THE COMPLEMENT-MEDIATED LYSIS OF UNSENSITIZED CELLS
- Studies on plasma kallikrein and its relationship to plasmin.
- A case of hereditary angioneurotic oedema, successfully treated with epsilon-aminocaproic acid. Studies on C'1 esterase inhibitor, C'1 activation, plasminogen level and histamine metabolism.
- Diagnostic complement fixation. I. A method.
- C6-Deficiency in Rabbits
- A CASE OF HEREDITARY ANGIONEUROTIC OEDEMA, SUCCESSFULLY TREATED WITH E-AMINOCAPROIC ACID
Cited by
- Inhibition of fibrinolytic activity of plasmin by suramin (antrypol) and trypan blue.
- Drug design using the example of the complement system inhibitors' development.
- Suramin as an archetypical compound in the development of growth factor antagonists for inhibition of genitourinary tumors.
- Suramin: with special reference to onchocerciasis.
- Suramin inhibits laminin- and thrombospondin-mediated melanoma cell adhesion and migration and binding of these adhesive proteins to sulfatide.
- Modulation by suramin of NK and monocytic cell-mediated cytotoxicity in human and murine cells.
- Suramin stimulates B-lymphocyte proliferation in the mouse
- Haemolysis induced by α-toxin from Staphylococcus aureus requires P2X receptor activation
- Modulation of CD4 by suramin
- Suramin blocks intracellular Ca2+ release and growth factor-induced increases in cytoplasmic free Ca2+ concentration.
- A trypanosome oligopeptidase as a target for the trypanocidal agents pentamidine, diminazene and suramin
- Suramin stimulates renal growth in the rat
- Suramin enhancement of the chemotherapeutic actions of cyclophosphamide or adriamycin of intramuscularly-implanted Ehrlich carcinoma.
- α-Hemolysin from Escherichia coli uses endogenous amplification through P2X receptor activation to induce hemolysis
- The effect of schedule, protein binding and growth factors on the activity of suramin
- Induction of lysosomal storage by suramin
- Suramin treatment for chronic active hepatitis B—toxic and ineffective
- Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6
- Effect of suramin on the mitogenic response of the human prostate carcinoma cell line PC‐3
- Artificial inhibition of the complement system
Related papers
- The ability of suramin to block CD4-gp120 binding is reversed in the presence of albumin
- Co-localization of suramin and serum albumin in lysosomes of suramin-treated human colon cancer cells.
- Inhibitory effect of suramin on receptor binding and cytotoxic activity of tumor necrosis factor alpha.
- The uptake of the trypanocidal drug suramin in combination with low-density lipoproteins by Trypanosoma brucei and its possible mode of action.
- Inhibition of angiogenesis by suramin.
- Suramin, an experimental chemotherapeutic drug, irreversibly blocks T cell CD45-protein tyrosine phosphatase in vitro.
- Effect of suramin on human esophageal cancer cells in vitro and in vivo.
- Cytostatic effects of suramin on prostate cancer cells cultured from primary tumors.
- Growth, morphology, and morphometry of human hypertrophic prostate cells treated with suramin in vitro